Viridian Stock Soars 8% After First Lumvoa Quarter Brings In $24.7 Million

Shares added $228 million in value as Lumvoa's launch topped 100 patients by September's end.

Share
Viridian Stock Soars 8% After First Lumvoa Quarter Brings In $24.7 Million

Viridian Therapeutics shares climbed 7.99% to $27.16 in Wednesday trading, as of 9:51 a.m. ET, adding $228 million in market value after the company reported $24.7 million in net product revenue from Lumvoa, its first quarter selling the drug. The biotech, which develops medicines for serious and rare autoimmune diseases, was on pace for its biggest one-day gain since October 19, when it rose 9.3%.

A launch ahead of expectations

Lumvoa treats thyroid eye disease, a rare autoimmune condition that inflames the tissue around the eye. It is Viridian's first commercial product. More than 100 patients were on therapy at the end of September, the company said.

CEO Steve Mahoney said on the earnings call that the launch "has exceeded expectations." Executives on the call declined to give market share or fourth-quarter guidance. About 30% of payers covered Lumvoa at the end of the third quarter, the company said on the call.

Spending shifts from labs to sales

The 10-Q shows lab spending dropped, with research and development at $70.1 million versus $86.3 million before. Sales and administrative costs climbed to $57.6 million, from $24.3 million.

Cash and marketable securities totaled $955.2 million, which the company said should fund its plans through profitability.

A stock still down for the year

Even with the jump, Viridian shares were down about 19% for the year as of Tuesday's close, while the S&P 500 was up about 11%. The stock had risen 30% over the previous month and sat 26% below its highest close of the past year, set on January 14.

Viridian is also developing elegrobart, an under-the-skin injection aimed at the same IGF-1R target. It plans to submit a license application to the FDA for it in the first quarter of 2027.

Viridian plans to file its FDA application for elegrobart in the first quarter of 2027.

Sources

More on Viridian Therapeutics

All Viridian Therapeutics (VRDN) coverage →